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Individual micron-sized solid particles from a Salamol® 
pharmaceutical inhaler are stably captured in air using an 
optical trap for the first time. Raman spectroscopy of the 
levitated particles allows online interrogation of composition 
and deliquescent phase change within a high humidity 
environment that mimics the particle’s travel from inhaler to 
lung.  
We investigate the physical and chemical evolution of the 
drug salbutamol sulphate (SS) from a Salamol® (manufacturer 
IVAX) pressurised metered-dose inhaler (pMDI) which contains a 
suspension of crystalline SS in 1,1,1,2-tetrafluoroethane (HFA-134a) 
propellant and minute amounts of ethanol. Upon actuation, SS is 
aerosolised generating micron sized particles.  We compare the 
pMDI generated SS particles to bulk crystalline sample of SS and 
nebulised aqueous droplets of SS.  This comparison permits the phase 
of the pMDI generated SS to be determined.  The bulk crystalline 
sample and the nebulized aqueous solution of SS are used as reference 
systems. 
An optical trap was used to probe the true aerosol phase of 
both the pMDI generated SS particles and the nebulised SS droplets.     
Optical trapping allowed for the stable levitation of the aerosol 
particles within a purpose built environmental chamber which 
mimicked the fast changing humidity encountered by pMDI- 
generated aerosol.  Optical trapping achieves particle levitation by 
balancing the gravitational force, and the viscous drag created by air 
flow, by an optical force1; it allows aerosols to be studied  in  a  
contact  free  manner  and  hence  without  the artefacts that contact 
with a surface can induce. 
Drugs are primarily delivered to the lung for the treatment 
of conditions local to the airway; for example anti-asthmatic drugs 
(e.g. salbutamol sulphate and beclometasone dipropionate)2. However, 
drug delivery to the lung is associated with a number of difficulties, 
including the relative inaccessibility of the lungs, necessitating the 
use of complex drug delivery devices to target the 
drug to the appropriate area of the airways. 
The pMDI is presently the device of choice, accounting for 
around 70% of inhaler sales in the UK3  and is the most  frequently  
used  device  for  asthma  and  chronic  obstructive pulmonary disease 
(COPD)4.  These devices contain the particles of the drug suspended 
(or occasionally dissolved) in a pressurised gas, typically a 
hydrofluoroalkane propellant, along with relatively few other 
excipients (principally cosolvents such as ethanol or surfactants such 
as oleic acid).   Actuating the device releases a metered volume of the 
suspension through an orifice contained within the pMDI housing5; 
the released pressurised suspension undergoes rapid flash evaporation 
and phase expansion and forms inhalable solid aerosol particles. 
The human respiratory tract efficiently filters atmospheric 
aerosols through the microphysics of impaction, sedimentation and 
diffusion. The size dependence of these competing processes results in 
particles of different sizes depositing in different regions of the 
respiratory tract6.   Particles in the size range 2-5 m are optimal for 
delivering drugs into the central regions of the lung and hence pMDI 
are formulated with micronized drug particles in this size range. 
If the inhaled particles are hygroscopic then their water 
content and hence size and aerodynamic properties are dependent 
upon the environmental relative humidity (RH) and the trajectory of 
the aerosol particles though this environment. The RH environment 
of  a  particle  exiting  the  pMDI  has  three  distinct  regions:  (1) 
completely dry at the initial point of injection as the aerosol is 
released from the canister, (2) at ambient RH as the patient inhales 
both the aerosol and the ambient atmosphere, and finally (3) high 
RH as the drug particles enters into the wet walled respiratory tract. 
The change in RH from phase (2) to (3) is not monotonic. As the 
particle travels deeper into the respiratory system it encounters 
increasingly higher humidities: ~40% in the mouth, ~60% in the 
pharynx, to finally approaching near water saturation ~99.5% in the 
deep airways6. The timescale of inhalation, and particle impaction, is 
~10 s. Patients using pMDIs are advised to actuate the device whilst 
simultaneously inhaling slowly and steadily for 4 s, followed by a 
breath-hold of 10 s to promote deposition by gravitational 
sedimentation7. 
Hygroscopic particles moving from a region of low 
ambient humidity into one of high humidity would be expected to 
increase in size due to water uptake.  A change in particle size will 
influence the site of particle deposition in the lung following 
inhalation8.  A particle predicted to deposit in the central regions of 
the lung may, if substantial growth is experienced, deposit higher in 
the respiratory tract than expected, potentially resulting in reduced 
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therapeutic efficacy and increased incidence of side effects (e.g. oral 
candidiasis following deposition of corticosteroids in the oropharynx).  
To mitigate these negative implications, the hygroscopic properties of 
respirable drug formulations need to be understood.  In particular the 
kinetics of deliquescence and particle growth need to be measured 
over the timescale (~10 s) of the journey of the aerosol from pMDI 
to lung. The kinetics could be significantly influenced by the 
morphology, size and/or phase of the particle and thus investigating 
them for the real pMDI-generated, contact-free particle is essential to 
obtain realistic results.  Previous studies have investigated the 
hygroscopicity of aqueous formulations of respirable drugs generated 
by nebulizer e.g. Haddrell et al. 20149. To the best of our knowledge 
this is the first in situ study of pMDI generated particles which 
represent the dominant commercial methodology for transporting 
aerosols into the lungs. 
The optical trap used in this study utilized a new design of 
counter-propagating dual beam (CPDB) configuration which we 
recently reported10,11.  The trap is optimized to trap solid micron sized 
particles over long timescales. This optical trapping configuration 
can readily capture non-spherical aerosol particles.  The counter-
propagating trapping beams are generated from the output of a  
Nd:Yag  laser  operating  at 1064  nm (Ventus,  Laser  Quantum). 
Typical laser powers used are 14 mW through the top and 
10 mW through the bottom objective lenses (see Fig. 1).  To achieve 
stable trapping the focal separation between the top and bottom beams 
was adjusted to ~10 m which allowed for stable levitation of the 
same particle for long time periods (> 1 hour). Most experiments were 
carried out over shorter, medically relevant timescales. 
 
 
 
Fig. 1. Schematic cartoon of the experimental setup showing the 
trapping and Raman laser paths and high humidity particle trap. 
 
The pMDI inhaler is discharged under ambient laboratory 
relative humidity (ca. 30%) and is directed into a small bespoke 
environment chamber, using a 20 cm length of Teflon tubing (6 mm 
internal diameter). Inside the environmental chamber the relative 
humidity can be varied, and very high subsaturated relative humidities 
(>98%) can be obtained. 
The experiments were performed at ambient laboratory 
temperature ca. 20 C.   Within the chamber the humidity and 
temperature were measured using a probe (Sensirion SHT75) 
positioned within ~1 cm of the trapping position. High humidity 
conditions were achieved using a water reservoir within the 
chamber.  Lower humidity conditions were generated by flowing dry 
nitrogen, generated from liquid nitrogen boil-off, through the 
chamber using a flow controller (Bronkhorst MV-301) with flow 
rates up to 200 sccm.  The time taken from particle release from 
pMDI  to  levitation  within  the  optical  trap  was  on  the  order  of 
seconds and hence the chamber could closely replicate the residence 
time and the RH trajectory of the particle in the lung. 
Aqueous droplets of SS were generated from a 0.05 M 
solution of SS (99% Alfa Aesar) in MilliQ water using an ultrasonic 
nebulizer (Schill Mobil Aerosonic 3060).  No attempt was made to 
replicate the minute amounts of ethanol cosolvents present in the 
Salamol® pMDI formulation and the role of ethanol is assumed to 
be negligible.  The solution generated droplets were trapped within the 
CPDB trap in the diameter size range 1 – 2 µm. 
To obtain spectroscopic information regarding particle 
composition a 514.5 nm Ar-ion laser (Innova 308C, Coherent) was 
focused onto the trapped particle through the lower objective with a 
power of 2 mW at focus (see Fig. 1).  This light source was used to 
generate both Raman and fluorescent (if present) signal which 
provide compositional information about the probed particle.  Both 
the Raman and fluorescent signal were directed to a spectrograph 
(Spectrapro 2500i, 1200 groove blazed at 500 nm) and imaged onto a 
CCD camera (Princeton Instruments, Spec10).  Each particle was 
only subjected to the 514.5 nm laser for 30 s to minimize heating and 
fluorescent bleaching effects12. This necessitates using fresh particles 
for every measurement. In addition to spectroscopic interrogation the 
trapped particles/droplets were imaged using brightfield microscopy.   
For more detail on the optical strategy, see Rkiouak et al. 201410. 
Optical trapping of particles can lead to particle heating 
through absorption of the laser radiation incident on the particle.  The 
extent of the heating depends upon the characteristics of the laser 
beam (wavelength, power and beam profile) and the absorption 
characteristics of the particle and surrounding medium13,14.  The 
increase in particle temperature above the ambient conditions, caused 
by absorption of the 514.5 and 1064 nm laser beams, is estimated  
using an approach similar to Knox and Reid15.  At the typically used 
laser powers it is estimated that a pure salbutamol sulphate particle of 
2 µm diameter would be 1.4 C warmer than the ambient conditions 
(see supplementary information).   
The optical trap configuration was extremely successful at 
trapping solid pMDI generated particles over a range of particle sizes 
and shapes.  The trapped particle size ranged from ca.  1 – 3 m. The 
measured asymmetry factor corresponded to particle shapes ranging 
from spheres to rods (Fig. 2).  The trap only ever contains one particle 
at a time as observed through bright field microscopy. Panel A in Fig. 
2 provides representative brightfield microscopy images   of   levitated   
pMDI   particles   with   asymmetry increasing from left to right.   The 
brightfield images of SS nebulised droplets and SS particles at high 
humidity both display more intense illumination at the centre of the 
particle, typical for the illumination of micro-spheres. Dry particles do 
not display this characteristic. 
Panel B compares the particle size histograms of particles 
caught within the optical trap and the total particle output from the 
pMDI. The C panels compare the sphericity of optically trapped 
particles, under high and low humidity conditions, with the total 
pMDI output obtained by imaging a coverslip at ambient RH. 
The size and sphericity of the total output from the pMDI 
is measured by releasing several puffs of the pMDI into the 
environmental chamber, without the optical trap active, and letting 
the   particles   settle   onto   the   coverslip   through   gravitational 
sedimentation.  The sizes and shapes of the resulting particle 
ensemble are then imaged using the brightfield microscope.  Particle 
size and shape were analysed using the image analysis software 
ImageJ (release 1.48) with particle size defined by the longest axis of 
the particle, and the particle sphericity defined by the reciprocal of 
the aspect ratio.  The measured particle size was calibrated using a 
graticule placed on the microscope. 
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Fig. 2. Imaging, characterising and comparing levitated particle 
with total pMDI output on coverslip.  Panel A - Example images 
of levitated SS particles with sphericity decreasing from left to 
right (scale bar = 2 m).   Panel B – Histograms of particle 
diameter (major axis).   Panel C – Histograms of particle 
sphericity caught in the optical trap under low (C1) and high 
(C2) RH conditions, and output collected on cover slip (C3).  The 
histograms are constructed from data from 62 optically levitated 
particles and 534 particles on the coverslip. 
 
In Fig. 2 panel B, the optical trap captures particles that are 
representative of the full output size range of the pMDI.  The modal 
size for both the levitated particles and full inhaler output is ~2 m.  
However, the optical trap’s particle size distribution is narrower. It 
does not stably capture the smallest (< 1m) or the larger particles 
(> 3.5 m) that are observed in the full output of the pMDI.  The 
observed trapped particle sizes and shapes were consistent with the 
measured aerosol output of pMDI from previous studies16. Under low 
RH conditions, the particles caught in the optical trap tend to be more 
spherical than the average particle exiting the pMDI (Fig. 2 C2 vs. 
Fig. 2 C3). This is likely due to the optical trap requiring some 
degree of symmetry in the particle shape for efficient trapping.  The 
sphericity of the trapped particles increases   significantly   under   
high   humidity   conditions, suggesting that water uptake by the 
particles increases particle sphericity (Fig. 2 C1).  No increase in 
average size was observed between low and high RH particles because 
the trap is optimized to a certain size range (~1–3 µm). 
The chemical and physical properties of the SS aerosol 
particle were followed using optical imaging, Raman spectroscopy 
and fluorescence spectroscopy. Raman spectra of optically trapped 
pMDI generated particles were measured over a wide range of RH 
(10-98%).  The spectra of pMDI particles were compared to the 
spectra from both bulk crystalline SS material deposited on a coverslip 
and optically trapped aqueous droplets of SS generated through 
nebulization (Fig. 3). The Raman spectrum of the crystalline SS from 
this study is similar to that previously recorded by Ali et al. but the 
spectral resolution in this study is greater17. The four largest intensity 
peaks at 780, 978, 1255 and 1615 rel. cm-1 are assigned to (C-C-O), 
(COH), (CH) and hydrogen bonded C-OH, respectively17.  The 
spectra of SS droplets generated from nebulization of aqueous SS 
contain a strong fluorescence signal superimposed upon the SS Raman 
peaks which are significantly broadened compared to the crystalline 
sample.   The Raman peak broadening in solution is likely due to the 
increase in vibrational energy configurations of the SS once water 
molecules are available for interaction via hydrogen bonding. Previous 
studies have also observed the fluorescence of solution phase SS18,19. 
The pMDI generated particles show two distinct spectra 
which are dependent upon RH.  At RH below ~92% the spectra are 
near-identical to the bulk crystalline material, confirming that the 
particles generated by the pMDI are largely crystalline in composition 
as they exit the pMDI.  The particles caught in the chamber at RH 
greater than ~92% show similar spectra but with significant peak 
broadening similar to the nebulised SS droplets.  All four major peaks 
(780, 978, 1255 and 1615 rel. cm-1) and the 750 rel. cm-1 peak show 
significant broadening at elevated RH, as shown in Fig. 3.  There is 
also significant growth in the peak at 1450 rel. cm-1. 
We attribute the step change in peak broadening at ~92% 
RH to a previously unreported SS deliquescent phase transition.  We 
note that amorphous SS particles have a distinct Raman spectrum20 
and therefore the transformation at ca. 92% RH is unlikely to be 
caused by a crystalline to amorphous phase transition.   
To further investigate the phase transition we looked at the 
peak broadening in more detail.  In particular, we investigated the 750 
and 780 rel. cm-1 peaks.  These peaks were chosen because they reside 
in a spectrally simple region and can be successfully fitted with two 
Lorentzian profiles with low associated error.  The results of the 780 
rel. cm-1 peak fitting are shown in the right panel of Fig. 3.  There is a 
large and obvious change in the peak width of the 780 cm-1 band after 
deliquescence.  Before deliquescence the average full width at half 
maximum (FWHM) is 6.5±0.7 rel. cm-1 and after deliquescence the 
width is 28.3±1.8 rel. cm-1, where the errors are 1.   The FWHM 
width of 750 cm-1 peak also changes significantly upon deliquescence 
with the pre-deliquescence and post-deliquescence values equal to 
6.0±0.9 rel. cm-1 and 11.6±1.4 rel. cm-1, respectively.   The peak 
broadening analysis determines the RH value at which the 
deliquescence phase transition occurs: 91.9 ± 2.7%. The error is 
dominated by the RH probe accuracy as stated by the manufacturer. 
Simple peak broadening analysis on the other three major 
peaks (978, 1255, 1615 rel. cm-1) give qualitatively very similar 
results with a clear transition occurring at ca. 92% RH.  Notably, the 
phase transition is possibly only partial on the timescale of the 
experiment, as evidenced by the lack of complete particle sphericity in 
all particles (Fig. 2 C1). However, the lack of sphericity could also be 
largely explained by error in the particle size measurement21. 
Interestingly, no fluorescence signal was observed from 
the levitated particle at RH either above or below the deliquescence 
point.  However, fluorescence is highly sensitive to the presence and 
concentration of solvents as well as pH22. A polar solvent like  water 
can  lead  to  lower  energy  fluorescence emission at longer 
wavelengths22.   Hence we would expect the fluorescence properties 
of nebulized droplets to be distinct from particles generated by a 
pMDI regardless of the RH due to the higher water content of 
nebulized particles. 
   
 
Fig. 3. Left panel: Offset Raman spectra of SS. Black line – 
Raman signal of crystalline SS (Alfa Aesar) deposited on the cover 
slip. Blue, brown, purple and green line – Raman signal from a 
single SS particle injected from the pMDI (Salamol®) into the 
environmental chamber and optically trapped at 12, 92, 94 and 
98% RH, respectively. Red line – Raman and fluorescence signal 
COMMUNICATION Journal Name 
4 | J. N am e . , 2 0 1 2 , 00 , 1 - 3 This journal is © The Royal Society of Chemistry 2012 
 
 
from single SS droplet generated by nebulization of aqueous SS 
solution. Right panel: Width (FWHM of fitted Lorentzian 
function) of the peak at 780 cm-1, which is highlighted by the blue 
band in the left panel. The yellow band indicates the SS 
deliquescence point. 
 
We provide a new methodology to study the physical and 
chemical characteristics of SS aerosol directly as it exits from a 
commercially available pMDI without changing its physical-chemical 
properties. Furthermore we interrogate the changes in aerosol 
characteristics that occur once the aerosol enters into a purpose built 
high humidity environment chamber which is used as a proxy for the 
human respiratory tract. This study focused on the output from a 
Salamol® inhaler, but the technique presented should be universal for 
all pMDI devices.  SS particles are observed to deliquesce at 91.9 ± 
2.7% RH as evidenced by three separate pieces of information: 
significant peak broadening in the Raman spectrum, increased particle 
sphericity and the emergence of a central bright spot within the 
brightfield images which is indicative of droplets.   Thus, following 
release from the Salamol® pMDI into the high RH environment of 
the respiratory tract, crystalline SS takes up water via 
deliquescence, resulting in an increase in particle sphericity.  This 
change in particle size, phase and morphology will affect the 
aerodynamic properties of the aerosol, and should be considered when 
modelling the aerosolization performance of inhalation products.  In 
addition, exposure to high RH results in the change of crystalline to 
liquid phase which will almost certainly promote drug dissolution, and 
hence the kinetics of drug uptake, following the deposition of the 
droplet onto the epithelial lining of the respiratory tract.  The reported 
experiments were performed at a temperature lower than the human 
body and at RH slightly less than saturation. Future work will focus 
on more realistic proxies for the respiratory tract. 
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